Correlation between prolonged menopausal hormonotherapy and indicators of vascular and replicative aging in womenстатьяИсследовательская статья
Статья опубликована в журнале из списка RSCI Web of Science
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 20 февраля 2024 г.
Аннотация:Objective. To evaluate the impact of prolonged menopausal hormonotherapy (MHT) on women’s biological age indicators.
Material and methods. The study included 25 women, who received MHT: 14 of them had timely menopause and 11 of them
had premature ovarian insufficiency (POI). The criteria for inclusion of patients with menopause in the study were: age ≥50 years,
menopause ≥5 years, MHT ≥5 years. The criteria for inclusion of patients with POI in the study were: age <40 years, POI eligibility, MHT ≥5 years. Control group consisted of women, who had not received MHT, and men: 14 women with timely menopause
for more than 5 years, aged ≥50 years, and 11 women with continued menstruation, aged <40 years, 28 men aged ≥50 years
and 11 men aged <40 years. The criteria for exclusion were: refusal to participate in the study, oncological disease in active phase
or remission less than 5 years, the presence of cardiovascular diseases (except hypertension), morbid obesity. All patients were
performed biochemical blood test, pulse wave velocity (PWV) and measured the length of telomere in peripheral mononuclear
blood cells by amplification method.
Results. The average telomere’s length in women, who had received MHT, was statistically significant less than in women, who had not taken MHT, as well as in men of appropriate age. Statistically significant differences by the telomeres’ length
in men and women, who had not received MHT, was not found. Correlation analysis of telomeres’ length with the age of women
and menopause duration revealed the significant negative moderate correlations: R= –0.365, p=0.022 and R= –0.319, p=0.047 respectively. PWV, as a marker of artery rigidity, did not differ between groups. The average telomeres’ length in young men was comparable to the telomeres’ length in healthy women and women with POI, who had received MHT. PWV also did not differ between
groups of young patients. The average glucose level was lower and the average high density lipoproteins were higher in women
taking MHT. The regression analysis based on multiple confounders (age of women and duration of MHT) in the group of postmenopausal women found that the main factor associated with telomeres’ length was MHT.
Conclusion. This study demonstrates a direct negative correlation between telomeres’ length and age of patients, and the absence
of sex dependence. The protective role of menopausal hormonotherapy in women relating to telomeres’ length and rigidity of magistral arteries has not been proved, but menopausal hormonotherapy is associated with more favorable metabolic profile in women with timely menopause. Longitudinal studies in parallel groups are necessary to determine the role of menopausal hormonotherapy in related to replicative aging.